R2 Technologies develops CryoAesthetic™ medical devices and commercially launched its first product, Glacial Rx, earlier in the year; the device is FDA‑cleared to remove benign lesions and to temporarily reduce pain, swelling and inflammation. The company is accelerating U.S. commercialization of Glacial Rx and is taking orders from aesthetic providers who want to offer the treatment in‑office. R2 plans to expand its corporate footprint—growing its presence in Silicon Valley and establishing a satellite office in Miami—and to fuel global growth and future product rollouts. To meet demand the company is accelerating manufacturing and ramping up marketing to drive education and awareness across consumer and professional channels. R2 was founded in 2014, licensed IP from Massachusetts General Hospital, and works with scientific founders and luminaries in aesthetic medicine. The company describes itself as shifting to a revenue‑driving phase following Glacial Rx’s commercial launch. R2 Technologies develops medical devices that use proprietary "cold technology" to treat aesthetic and medical skin conditions, including a skin lightening and tone-evening offering. The company has received FDA market clearance for its second-generation R2 Dermal Cooling System, a cryosurgical instrument intended for removal of benign skin lesions. R2 licensed core IP from Blossom Innovations and researchers at Massachusetts General Hospital and other academic collaborators. Proceeds from recent financing are being used to commercialize its CryoAesthetic technology, add key staff, and launch a pre-order program planned for this summer. R2 aims to capture a significant foothold in the $22 billion global skin lightening and brightening market. The company is a portfolio business of Pansend Life Sciences (a subsidiary of HC2 Holdings), was founded in late 2014, and is located in San Ramon, California.

Total raised

$25M

Funding rounds

2

Latest round

Series C

Latest activity

Jul 2021